Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b tarlatamab + AMG 404 in relapsed small cell lung cancer
jRCT2031220086Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of tarlatamab and zeluvalimab in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoints: Number of participants who experienced dose-limiting toxicity (DLT) and Number of participants with treatment-emergent adverse events (TEAEs). Started Sep 2021; status: completed.
02
Drugs
tarlatamabzeluvalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031220086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220086.